The grateful dead: Damage-associated molecular pattern molecules and reduction/oxidation regulate immunity

Immunological Reviews

Volumn 220, Issue 1, 2007, Pages 60-81

  Lotze, Michael T ^a   Zeh, Herbert J ^a   Rubartelli, Anna ^b   Sparvero, Louis J ^a   Amoscato, Andrew A ^a   Washburn, Newell R ^c   DeVera, Michael E ^a   Liang, Xiaoyan ^a   Tör, Mahmut ^d   Billiar, Timothy ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

DAMPs; HMGB1; PAMPs; RAGE; Redox; TLR4

Indexed keywords

CHROMOSOME PROTEIN; DAMAGE ASSOCIATED MOLECULAR PATTERN MOLECULE; DNA; HIGH MOBILITY GROUP BOX CHROMOSOMAL PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN 1 RECEPTOR; OLIGONUCLEOTIDE; OXIDOREDUCTASE; PLATINUM; PROTEIN; RECEPTOR; RECEPTOR FOR ADVANCED GLYCATION END PRODUCT; RETINOIC ACID INDUCIBLE GENE 1 LIKE RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; BONE MARROW CELL; CELL ACTIVATION; CELL DAMAGE; CELL DEATH; CELL MIGRATION; CELL STRESS; DNA BINDING; DNA CROSS LINKING; ENDOTHELIUM; EOSINOPHIL; GLYCATION; GRANULOCYTE; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; ISCHEMIA; METAZOON; MOLECULAR MECHANICS; NEUTROPHIL; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROKARYOTE; PROTEIN FOLDING; REDUCTION; REPERFUSION INJURY; REVIEW; TUMOR CELL; WOUND HEALING;

ANIMALS; APOPTOSIS; GRANULOCYTES; HMGB1 PROTEIN; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; MICE; NECROSIS; NEOPLASMS; OXIDATION-REDUCTION; RECEPTORS, IMMUNOLOGIC; REPERFUSION INJURY;

EID: 35748945719     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2007.00579.x     Document Type: Review

References (249)

1. Land W, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994 57 : 211 217.
2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994 12 : 991 1045.
3. Chinchilla D, Bauer Z, Regenass M, Boller T, Felix G. The Arabidopsis receptor kinase FLS2 binds flg22 and determines the specificity of flagellin perception. Plant Cell 2006 18 : 465 476.
4. Yamaguchi Y, Pearce G, Ryan CA. The cell surface leucine-rich repeat receptor for AtPep1, an endogenous peptide elicitor in Arabidopsis, is functional in transgenic tobacco cells. Proc Natl Acad Sci USA 2006 103 : 10104 10109.
5. Takabatake R, Seo S, Ito N, Gotoh Y, Mitsuhara I, Ohashi Y. Involvement of wound-induced receptor-like protein kinase in wound signal transduction in tobacco plants. Plant J 2006 47 : 249 257.
6. Seo S, Sano H, Ohashi Y. Jasmonate-based wound signal transduction requires activation of WIPK, a tobacco mitogen-activated protein kinase. Plant Cell 1999 11 : 289 298.
7. Dangl JL, Jones JD. Plant pathogens and integrated defence responses to infection. Nature 2001 411 : 826 833.
8. Shiu SH, Bleecker AB. Expansion of the receptor-like kinase/Pelle gene family and receptor-like proteins in Arabidopsis. Plant Physiol 2003 132 : 530 543.
9. Fritz-Laylin LK, Krishnamurthy N, Tor M, Sjolander KV, Jones JD. Phylogenomic analysis of the receptor-like proteins of rice and Arabidopsis. Plant Physiol 2005 138 : 611 623.
10. Di Matteo A, et al. The crystal structure of polygalacturonase-inhibiting protein (PGIP), a leucine-rich repeat protein involved in plant defense. Proc Natl Acad Sci USA 2003 100 : 10124 10128.
11. Meyers BC, Kozik A, Griego A, Kuang H, Michelmore RW. Genome-wide analysis of NBS-LRR-encoding genes in Arabidopsis. Plant Cell 2003 15 : 809 834.
12. West SA, Griffin AS, Gardner A, Diggle SP. Social evolution theory for microorganisms. Nat Rev Microbiol 2006 4 : 597 607.
13. Mehdiabadi NJ, et al. Social evolution: kin preference in a social microbe. Nature 2006 442 : 881 882.
14. Dietrich LE, Price-Whelan A, Petersen A, Whiteley M, Newman DK. The phenazine pyocyanin is a terminal signalling factor in the quorum sensing network of Pseudomonas aeruginosa. Mol Microbiol 2006 61 : 1308 1321.
15. Chen G, Zhuchenko O, Kuspa A. Immune-like phagocyte activity in the social amoeba. Science 2007 317 : 678 681.
16. Cooper RM. Cell-wall degrading enzymes. In : Wood RKS, Jellis GJ, eds. Plant, Disease: Infection Damage and Loss. Oxford : Blackwell Publishing, 1984 : 13 27.
17. Thaler JS, Owen B, Higgins VJ. The role of the jasmonate response in plant susceptibility to diverse pathogens with a range of lifestyles. Plant Physiol 2004 135 : 530 538.
18. Fagard M, et al. Arabidopsis thaliana expresses multiple lines of defense to counterattack Erwinia chrysanthemi. Mol Plant Microbe Interact 2007 20 : 794 805.
19. Pearce G, Strydom D, Johnson S, Ryan CA. A polypeptide from tomato leaves induces wound-inducible proteinase inhibitor proteins. Science 1991 253 : 895 897.
20. Narvaez-Vasquez J, Pearce G, Orozco-Cardenas ML, Franceschi VR, Ryan CA. Autoradiographic and biochemical evidence for the system translocation of systemin in tomato plants. Planta 1995 195 : 593 600.
21. Ryan CA, Pearce G. Systemins: a functionally defined family of peptide signals that regulate defensive genes in Solanaceae species. Proc Natl Acad Sci USA 2003 100 (Suppl.) : 14577 14580.
22. Huffaker A, Pearce G, Ryan CA. An endogenous peptide signal in Arabidopsis activates components of the innate immune response. Proc Natl Acad Sci USA 2006 103 : 10098 10103.
23. Huffaker A, Ryan CA. Endogenous peptide defense signals in Arabidopsis differentially amplify signaling for the innate immune response. Proc Natl Acad Sci USA 2007 104 : 10732 10736.
24. Jones JD, Dangl JL. The plant immune system. Nature 2006 444 : 323 329.
25. Zhang S, Klessig DF. The tobacco wounding-activated mitogen-activated protein kinase is encoded by SIPK. Proc Natl Acad Sci USA 1998 95 : 7225 7030.
26. Kim CY, Zhang S. Activation of a mitogen-activated protein kinase cascade induces WRKY family of transcription factors and defense genes in tobacco. Plant J 2004 38 : 142 151.
27. Ge X, et al. AtNUDT7, a negative regulator of basal immunity in arabidopsis, modulates two distinct defense response pathways and is involved in maintaining redox homeostasis. Plant Physiol 2007 145 : 204 215.
28. Allan AC, Fluhr R. Two distinct sources of elicited reactive oxygen species in tobacco epidermal cells. Plant Cell 1997 9 : 1559 1572.
29. Torres MA, Jones JD, Dangl JL. Reactive oxygen species signaling in response to pathogens. Plant Physiol 2006 141 : 373 378.
30. Kurilich AC, et al. Carotene, tocopherol, and ascorbate contents in subspecies of Brassica oleracea. J Agric Food Chem 1999 47 : 1576 1581.
31. Wong HL, Sakamoto T, Kawasaki T, Umemura K, Shimamoto K. Down-regulation of metallothionein, a reactive oxygen scavenger, by the small GTPase OsRac1 in rice. Plant Physiol 2004 135 : 1447 1456.
32. Kariola T, Brader G, Li J, Palva ET. Chlorophyllase 1, a damage control enzyme, affects the balance between defense pathways in plants. Plant Cell 2005 17 : 282 294.
33. Chang CC, Ball L, Fryer MJ, Baker NR, Karpinski S, Mullineaux PM. Induction of ascorbate peroxidase 2 expression in wounded Arabidopsis leaves does not involve known wound-signalling pathways but is associated with changes in photosynthesis. Plant J 2004 38 : 499 511.
34. Matamoros MA, et al. Molecular analysis of the pathway for the synthesis of thiol tripeptides in the model legume Lotus japonicus. Mol Plant Microbe Interact 2003 16 : 1039 1046.
35. Zimmermann P, Heinlein C, Orendi G, Zentgraf U. Senescence-specific regulation of catalases in Arabidopsis thaliana (L.) Heynh. Plant Cell Environ 2006 29 : 1049 1060.
36. Alscher RG, Erturk N, Heath LS. Role of superoxide dismutases (SODs) in controlling oxidative stress in plants. J Exp Bot 2002 53 : 1331 1341.
37. Vieira Dos Santos C, Rey P. Plant thioredoxins are key actors in the oxidative stress response. Trends Plant Sci 2006 11 : 329 334.
38. Bören M, Höglund AS, Bozhikov P, Hansson C. Developmental regulation of a VEIDase caspase-like proteolytic activity in barley caryopsis. J Exp Bot 2006 57 : 3747 3753.
39. Bassham DC, et al. Autophagy in development and stress responses of plants. Autophagy 2006 2 : 2 11.
40. Greenberg JT. Degrade or die: a dual function for autophagy in the plant immune response. Dev Cell 2005 8 : 799 801.
41. Seay M, Patel S, Dinesh-Kumar SP. Autophagy and plant innate immunity. Cell Microbiol 2006 8 : 899 906.
42. Vierstra RD. Proteolysis in plants: mechanisms and functions. Plant Mol Biol 1996 32 : 275 302.
43. Deshaies RJ. Phosphorylation and proteolysis: partners in the regulation of cell division in budding yeast. Curr Opin Genet Dev 1997 7 : 7 16.
44. Ingvardsen C, Veierskov B. Ubiquitin- and proteasome-dependent proteolysis in plants. Physiol Plant 2001 112 : 451 459.
45. Ellis C, Turner JG, Devoto A. Protein complexes mediate signalling in plant responses to hormones, light, sucrose and pathogens. Plant Mol Biol 2002 50 : 971 980.
46. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004 430 : 257 263.
47. Medzhitov R, Janeway C Jr. Innateimmunity. N Engl J Med 2000 343 : 338 344.
48. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006 26 : 430 437.
49. Prinz M, et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 2006 116 : 456 464.
50. Fields ML, et al. Exogenous and endogenous TLR ligands activate anti-chromatin and polyreactive B cells. J Immunol 2006 176 : 6491 6502.
51. Lamphier MS, Sirois CM, Verma A, Golenbock DT, Latz E. TLR9 and the recognition of self and non-self nucleic acids. Ann NY Acad Sci 2006 1082 : 31 43.
52. Tsung A, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005 201 : 1135 1143.
53. Yang R, et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 2006 12 : 105 114.
54. Samanta MP, et al. The transcriptome of the sea urchin embryo. Science 2006 314 : 960 962.
55. Scheer JM, Ryan CA Jr. The systemin receptor SR160 from Lycopersicon peruvianum is a member of the LRR receptor kinase family. Proc Natl Acad Sci USA 2002 99 : 9585 9590.
56. Montoya T, Nomura T, Farrar K, Kaneta T, Yokota T, Bishop GJ. Cloning the tomato curl3 gene highlights the putative dual role of the leucine-rich repeat receptor kinase tBRI1/SR160 in plant steroid hormone and peptide hormone signaling. Plant Cell 2002 14 : 3163 3176.
57. Tomes L, et al. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 2003 81 : 61 69.
58. Matsue H, et al. Generation and function of reactive oxygen species in dendritic cells during antigen presentation. J Immunol 2003 171 : 3010 3018.
59. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci USA 2006 103 : 12831 12836.
60. Fraternale A, et al. Antiviral and immunomodulatory properties of new pro-glutathione (GSH) molecules. Curr Med Chem 2006 13 : 1749 1755.
61. Blakytny R, Erkell LJ, Brunner G. Inactivation of active and latent transforming growth factor beta by free thiols: potential redox regulation of biological action. Int J Biochem Cell Biol 2006 38 : 1363 1373.
62. Miyoshi N, Oubrahim H, Chock PB, Stadtman ER. Age-dependent cell death and the role of ATP in hydrogen peroxide-induced apoptosis and necrosis. Proc Natl Acad Sci USA 2006 103 : 1727 1731.
63. Monticelli S, et al. MicroRNA profiling of the murine hematopoietic system. Genome Biol 2005 6 : R71.
64. Lackman RL, Jamieson AM, Griffith JM, Geuze H, Cresswell P. Innate immune recognition triggers secretion of lysosomal enzymes by macrophages. Traffic 2007 8 : 1179 1189.
65. Lackman RL, Cresswell P. Exposure of the promonocytic cell line THP-1 to Escherichia coli induces IFN-gamma-inducible lysosomal thiol reductase expression by inflammatory cytokines. J Immunol 2006 177 : 4833 4840.
66. Phan UT, Lackman RL, Cresswell P. Role of the C-terminal propeptide in the activity and maturation of gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc Natl Acad Sci USA 2002 99 : 12298 12303.
67. Phan UT, Arunachalam B, Cresswell P. Gamma-interferon-inducible lysosomal thiol reductase (GILT). Maturation, activity, and mechanism of action. J Biol Chem 2000 275 : 25907 25914.
68. Arunachalam B, Phan UT, Geuze HJ, Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon-inducible lysosomal thiol reductase (GILT). Proc Natl Acad Sci USA 2000 97 : 745 750.
69. Zheng W, Chen X. Cloning and expression analysis of interferon-gamma- inducible-lysosomal thiol reductase gene in large yellow croaker (Pseudosciaena crocea). Mol Immunol 2006 43 : 2135 2141.
70. Hastings KT, Lackman RL, Cresswell P. Functional requirements for the lysosomal thiol reductase GILT in MHC class II-restricted antigen processing. J Immunol 2006 177 : 8569 8577.
71. Maric M, et al. Defective antigen processing in GILT-free mice. Science 2001 294 : 1361 1365.
72. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005 5 : 331 342.
73. Wang H, et al. HMG-1 as a late mediator of endotixin lethality in mice. Science 1999 285 : 248 251.
74. Kim JY, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am J Physiol Lung Cell Mol Physiol 2005 288 : L958 L965.
75. Park JS, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006 290 : C917 C924.
76. Park JS, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004 279 : 7370 7377.
77. Yu M, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006 26 : 174 179.
78. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004 16 : 3 9.
79. Fitzgerald KA, Rowe DC, Golenbock DT. Endotoxin recognition and signal transduction by the TLR4/MD2-complex. Microbes Infect 2004 6 : 1361 1367.
80. Triantafilou M, Miyake K, Golenbock DT, Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J Cell Sci 2002 115 : 2603 2611.
81. Triantafilou M, et al. Combinational clustering of receptors following stimulation by bacterial products determines lipopolysaccharide responses. Biochem J 2004 381 : 527 536.
82. Triantafilou M, Triantafilou K. Receptor cluster formation during activation by bacterial products. J Endotoxin Res 2003 9 : 331 335.
83. Olsson S, Sundler R. The role of lipid rafts in LPS-induced signaling in a macrophage cell line. Mol Immunol 2006 43 : 607 612.
84. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990 249 : 1431 1433.
85. Muta T, Takeshige K. Essential roles of CD14 and lipopolysaccharide- binding protein for activation of toll-like receptor (TLR)2 as well as TLR4 reconstitution of TLR2- and TLR4-activation by distinguishable ligands in LPS preparations. Eur J Biochem 2001 268 : 4580 4589.
86. Hornef MW, Normark BH, Vandewalle A, Normark S. Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med 2003 198 : 1225 1235.
87. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002 347 : 1593 1603.
88. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002 2 : 331 341.
89. Stewart SA, Ben-Porath I, Carey VJ, O'Connor BF, Hahn WC, Weinberg RA. Erosion of the telomeric single-strand overhang at replicative senescence. Nat Genet 2003 33 : 492 496.
90. Weinberg RA. Inadvertent cancer research. Cancer Biol Ther 2004 3 : 238 239.
91. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001 411 : 375 379.
92. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001 61 : 4961 4965.
93. Ferrandina G, et al. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002 87 : 1145 1152.
94. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 2002 62 : 6846 6849.
95. Cutler NS, et al. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 2003 63 : 1748 1751.
96. Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. The fibroblast: sentinel cell and local immune modulator in tumor tissue. Int J Cancer 2004 108 : 173 180.
97. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 2003 4 : 1405 1409.
98. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004 4 : 641 648.
99. DeMarco RA, Fink MP, Lotze MT. Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Mol Immunol 2005 42 : 433 444.
100. Zeh HJ III., Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 2005 28 : 1 9.
101. Janeway C. Immunogenicity signals 1, 2, 3... and 0. Immunol Today 1989 10 : 283 286.
102. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996 8 : 271 280.
103. Matzinger P. An innate sense of danger. Semin Immunol 1998 10 : 399 415.
104. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999 5 : 1249 1255.
105. Anderson CC, Matzinger P. Danger: the view from the bottom of the cliff. Semin Immunol 2000 12 : 231 238 discussion 57-344.
106. Janeway CA Jr. How the immune system protects the host from infection. Microbes Infect 2001 3 : 1167 1171.
107. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001 13 : 114 119.
108. Matzinger P. The danger model: a renewed sense of self. Science 2002 296 : 301 305.
109. Matzinger P. The danger model. Vox Sang 2004 87 (Suppl.) : 18.
110. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004 4 : 469 478.
111. Liu S, Salyapongse AN, Geller DA, Vodovotz Y, Billiar TR. Hepatocyte toll-like receptor 2 expression in vivo and in vitro: role of cytokines in induction of rat TLR2 gene expression by lipopolysaccharide. Shock 2000 14 : 361 365.
112. Quesniaux VJ, et al. Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative regulation of proinflammatory cytokines by mycobacterial lipomannans. J Immunol 2004 172 : 4425 4434.
113. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004 76 : 514 519.
114. Pinhal-Enfield G, et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol 2003 163 : 711 721.
115. Poltorak A, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998 282 : 2085 2088.
116. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998 95 : 588 593.
117. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003 37 : 1043 1055.
118. Salazar JC, et al. Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 2003 171 : 2660 2670.
119. Zheng SL, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004 64 : 2918 2922.
120. Taguchi A, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000 405 : 354 360.
121. Neeper M, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992 267 : 14998 15004.
122. Miki S, et al. Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem Biophys Res Commun 1993 196 : 984 989.
123. Schmidt AM, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995 96 : 1395 1403.
124. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997 272 : 16498 16506.
125. Huttunen HJ, Fages C, Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 1999 274 : 19919 19924.
126. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001 108 : 949 955.
127. Takada M, Koizumi T, Toyama H, Suzuki Y, Kuroda Y. Differential expression of RAGE in human pancreatic carcinoma cells. Hepatogastroenterology 2001 48 : 1577 1578.
128. Schenk S, Schraml P, Bendik I, Ludwig CU. A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer 2001 32 : 7 12.
129. Kuniyasu H, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002 196 : 163 170.
130. Sparatore B, et al. Stimulation of erythroleukaemia cell differentiation by extracellular high-mobility group-box protein 1 is independent of the receptor for advanced glycation end-products. Biochem J 2002 363 : 529 535.
131. Hirata K, Takada M, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepatogastroenterology 2003 50 : 1205 1207.
132. Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003 307 : 375 381.
133. Abe R, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004 122 : 461 467.
134. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect 2004 6 : 1219 1225.
135. Treutiger CJ, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003 254 : 375 385.
136. Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology 2004 51 : 928 930.
137. Rouhiainen A, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004 104 : 1174 1182.
138. Flohr AM, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res 2001 21 : 3881 3885.
139. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int J Cancer 2003 104 : 722 727.
140. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep 2003 10 : 445 448.
141. Kajino K, Yamamoto T, Hayashi J, Umeda T, Takahara T, Hino O. Recombination hot spot of hepatitis B virus genome binds to members of the HMG domain protein family and the Y box binding protein family; implication of these proteins in genomic instability. Intervirology 2001 44 : 311 316.
142. Schraml P, Bendik I, Ludwig CU. Differential messenger RNA and protein expression of the receptor for advanced glycosylated end products in normal lung and non-small cell lung carcinoma. Cancer Res 1997 57 : 3669 3671.
143. Hofmann HS, Hansen G, Burdach S, Bartling B, Silber RE, Simm A. Discrimination of human lung neoplasm from normal lung by two target genes. Am J Respir Crit Care Med 2004 170 : 516 519.
144. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004 18 : 1272 1282.
145. Gotte K, Usener D, Riedel F, Hormann K, Schadendorf D, Eichmuller S. Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes. Acta Otolaryngol 2002 122 : 546 552.
146. Eichmuller S, Usener D, Jochim A, Schadendorf D. mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp Dermatol 2002 11 : 292 301.
147. Bosserhoff AK, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997 57 : 3149 3153.
148. Deichmann M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999 17 : 1891 1896.
149. Takenaga K. Suppression of metastasis-associated S100A4 gene expression by gamma-interferon in human colon adenocarcinoma cells. Br J Cancer 1999 80 : 127 132.
150. Kimura K, et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000 16 : 1125 1131.
151. Komatsu K, et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 2000 83 : 769 774.
152. Rudland PS, et al. Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000 60 : 1595 1603.
153. Vuoristo MS, et al. The value of serum S-100beta and interleukins as tumour markers in advanced melanoma. Melanoma Res 2000 10 : 237 241.
154. Wollina U, Karte K, Hipler UC, Knoll B, Kirsch K, Herold C. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay. J Cancer Res Clin Oncol 2000 126 : 107 110.
155. Wang G, Rudland PS, White MR, Barraclough R. Interaction in vivo and in vitro of the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1. J Biol Chem 2000 275 : 11141 11146.
156. Yonemura Y, et al. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000 6 : 4234 5342.
157. Bronckart Y, et al. Development and progression of malignancy in human colon tissues are correlated with expression of specific Ca(2+)-binding S100 proteins. Histol Histopathol 2001 16 : 707 712.
158. Mohammed MQ, Abraha HD, Sherwood RA, MacRae K, Retsas S. Serum S100beta protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 2001 18 : 109 120.
159. Ninomiya I, et al. Increased expression of S100A4 and its prognostic significance in esophageal squamous cell carcinoma. Int J Oncol 2001 18 : 715 720.
160. Davies BR, et al. Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. J Pathol 2002 196 : 292 299.
161. Komatsu K, et al. Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology 2002 63 : 192 200.
162. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol 2002 23 : 39 44.
163. Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002 277 : 3658 3665.
164. Rosty C, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002 160 : 45 50.
165. Ryu B, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002 62 : 819 826.
166. Taylor S, Herrington S, Prime W, Rudland PS, Barraclough R. S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes. Br J Cancer 2002 86 : 409 416.
167. Andersen K, et al. Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. Br J Cancer 2003 88 : 1995 2001.
168. Cho YG, et al. Overexpression of S100A4 is closely related to the aggressiveness of gastric cancer. Apmis 2003 111 : 539 545.
169. Flatmark K, et al. Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 2003 200 : 589 595.
170. Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. J Clin Oncol 2003 21 : 106 112.
171. Mandinova A, et al. S100A13 mediates the copper-dependent stress-induced release of IL-1alpha from both human U937 and murine NIH 3T3 cells. J Cell Sci 2003 116 : 2687 2696.
172. Diederichs S, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004 64 : 5564 5569.
173. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 2004 82 : 508 515.
174. Emberley ED, Murphy LC, Watson PH. S100A7 and the progression of breast cancer. Breast Cancer Res 2004 6 : 153 159.
175. Flatmark K, et al. Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol 2004 25 : 31 40.
176. Ghavami S, Kerkhoff C, Los M, Hashemi M, Sorg C, Karami-Tehrani F. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J Leukoc Biol 2004 76 : 169 175.
177. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004 37 : 512 518.
178. Lin J, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem 2004 279 : 34071 34077.
179. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004 322 : 1111 1122.
180. Schmidt-Hansen B, et al. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004 23 : 5487 5495.
181. Schmidt-Hansen B, et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem 2004 279 : 24498 24504.
182. Miyazaki M, Sakaguchi M, Akiyama I, Sakaguchi Y, Nagamori S, Huh NH. Involvement of interferon regulatory factor 1 and S100C/A11 in growth inhibition by transforming growth factor beta 1 in human hepatocellular carcinoma cells. Cancer Res 2004 64 : 4155 4161.
183. Ulloa L, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002 99 : 12351 12356.
184. Wang H, et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999 126 : 389 392.
185. Rendon-Mitchell B, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003 170 : 3890 3897.
186. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005 106 : 609 616.
187. Messmer D, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004 173 : 307 313.
188. Agnello D, Wang H, Yang H, Tracey KJ, Ghezzi P. HMGB-1, a DNA-binding protein with cytokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine 2002 18 : 231 236.
189. Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE 2002 2002 : PE39.
190. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002 418 : 191 195.
191. Chu JJ, Ng ML. The mechanism of cell death during West Nile virus infection is dependent on initial infectious dose. J Gen Virol 2003 84 : 3305 3314.
192. Andersson U, Tracey KJ. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 2004 30 : 627 637, xi.
193. Jungas T, Verbeke P, Darville T, Ojcius DM. Cell death, BAX activation, and HMGB1 release during infection with Chlamydia. Microbes Infect 2004 6 : 1145 1155.
194. Basta G, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002 105 : 816 822.
195. Fehrenbach H, Kasper M, Tschernig T, Shearman MS, Schuh D, Muller M. Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung. Cell Mol Biol (Noisy-le-grand) 1998 44 : 1147 1157.
196. Fiuza C, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003 101 : 2652 2660.
197. Ito N, et al. Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leuk Biol 2007 81 : 75 83.
198. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 1992 256 : 234 237.
199. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 1994 91 : 10394 10398.
200. Locker D, Decoville M, Maurizot JC, Bianchi ME, Leng M. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism. J Mol Biol 1995 246 : 243 247.
201. Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999 399 : 708 712.
202. Pasheva EA, Ugrinova I, Spassovska NC, Pashev IG. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. Int J Biochem Cell Biol 2002 34 : 87 92.
203. Delalande O, Malina J, Brabec V, Kozelka J. Chiral differentiation of DNA adducts formed by enantiomeric analogues of antitumor cisplatin is sequence-dependent. Biophys J 2005 88 : 4159 4169.
204. Zhang CX, Chang PV, Lippard SJ. Identification of nuclear proteins that interact with platinum-modified DNA by photoaffinity labeling. J Am Chem Soc 2004 126 : 6536 6537.
205. Yaneva J, Leuba SH, van Holde K, Zlatanova J. The major chromatin protein histone H1 binds preferentially to cis-platinum-damaged DNA. Proc Natl Acad Sci USA 1997 94 : 13448 13451.
206. Yoshida Y, et al. P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res 2003 63 : 3729 3734.
207. Chao JC, Wan XS, Engelsberg BN, Rothblum LI, Billings PC. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin. Biochim Biophys Acta 1996 1307 : 213 219.
208. Wei M, Cohen SM, Silverman AP, Lippard SJ. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 2001 276 : 38774 38780.
209. Wei M, Burenkova O, Lippard SJ. Cisplatin sensitivity in Hmbg1-/- and Hmbg1+/+ mouse cells. J Biol Chem 2003 278 : 1769 1773.
210. Karymov M, Daniel D, Sankey OF, Lyubchenko YL. Holliday junction dynamics and branch migration: single-molecule analysis. Proc Natl Acad Sci USA 2005 102 : 8186 8191.
211. Strothkamp KG, Lippard SJ. Platinum binds selectively to phosphorothioate groups in mono- and polynucleotides: a general method for heavy metal staining of specific nucleotides. Proc Natl Acad Sci USA 1976 73 : 2536 2540.
212. Kadowaki N, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001 194 : 863 869.
213. Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis 2003 35 : 653 659.
214. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004 6 : 88 95.
215. Vollmer J, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004 34 : 251 262.
216. Bairey O, Kirgner I, Yakobi M, Hamdan A, Ben-Ari Z, Shaklai M. Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide. Am J Hematol 2002 69 : 281 284.
217. Richardson PG, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002 100 : 4337 4343.
218. Aydemir EO, Var A, Uyanik BS, Ilkgul O, Aydede H, Sakarya A. The protective mechanisms of defibrotide on liver ischaemia-reperfusion injury. Cell Biochem Funct 2003 21 : 307 310.
219. Corbacioglu S, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004 33 : 189 195.
220. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004 103 : 1968.
221. Eissner G, et al. Oligotide, a defibrotide derivative, protects human microvascular endothelial cells against fludarabine-induced activation, damage and allogenicity. Bone Marrow Transplant 2005 35 : 915 920.
222. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005 5 : 468 479.
223. Rothenfusser S, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004 103 : 2162 2169.
224. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003 9 : 3105 3114.
225. Lenert P, Rasmussen W, Ashman RF, Ballas ZK. Structural characterization of the inhibitory DNA motif for the type A (D)-CpG-induced cytokine secretion and NK-cell lytic activity in mouse spleen cells. DNA Cell Biol 2003 22 : 621 631.
226. Krieg AM. Signal transduction induced by immunostimulatory CpG DNA. Springer Semin Immunopathol 2000 22 : 97 105.
227. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997 186 : 1623 1631.
228. Krieg AM, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995 374 : 546 549.
229. Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol 2005 174 : 4579 4583.
230. Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol 2005 174 : 777 782.
231. Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB × NZW mice. Arthritis Rheum 2005 52 : 651 658.
232. Staveley-O'Carroll K, et al. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol 2003 171 : 697 707.
233. Lambrecht BN, Salomon B, Klatzmann D, Pauwels RA. Dendritic cells are required for the development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. J Immunol 1998 160 : 4090 4097.
234. Leckie MJ, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000 356 : 2144 2148.
235. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000 165 : 2950 2954.
236. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005 78 : 1 8.
237. Sun NK, Chao CC. The cytokine activity of HMGB1 - extracellular escape of the nuclear protein. Chang Gung Med J 2005 28 : 673 682.
238. Dumitriu IE, Baruah P, Bianchi ME, Manfredi AA, Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur J Immunol 2005 35 : 2184 2190.
239. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007 81 : 59 66.
240. Stenfeldt AL, Wenneras C. Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology 2004 112 : 605 614.
241. Hanford LE, et al. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2004 279 : 50019 50024.
242. Bierhaus A, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005 83 : 876 886.
243. Cormier SA, et al. Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 2006 79 : 1131 1139.
244. Hoppe G, Talcott KE, Bhattacharya SK, Crabb JW, Sears JE. Molecular basis for the redox control of nuclear transport of the structural chromatin protein HMGB1. Exp Cell Res 2006 312 : 3526 3538.
245. Adamko DJ, Wu Y, Gleich GJ, Lacy P, Moqbel R. The induction of eosinophil peroxidase release: improved methods of measurement and stimulation. J Immunol Methods 2004 291 : 101 108.
246. Fan J, Li Y, Vodovotz Y, Billiar TR, Wilson MA. Neutrophil NAD(P)H oxidase is required for hemorrhagic shock-enhanced TLR2 up-regulation in alveolar macrophages in response to LPS. Shock 2007 28 : 213 218.
247. Fan J, et al. Hemorrhagic shock induces NAD(P)H oxidase activation in neutrophils: role of HMGB1-TLR4 signaling. J Immunol 2007 178 : 6573 6580.
248. Fan J, Li Y, Vodovotz Y, Billiar TR, Wilson MA. Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation. Am J Physiol Lung Cell Mol Physiol 2006 290 : L738 L746.
249. Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007 28 : 429 436.